FMP
REGENXBIO Inc.
RGNX
NASDAQ
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
5.41 USD
-0.5 (-9.24%)
Latest RGNX News
Tony Dante
Mar 16, 2025
Understanding the Financial Health of REGENXBIO Inc. and Its Peers in the Biotech Sector
REGENXBIO Inc. (NASDAQ:RGNX) is a biotechnology company focused on developing gene therapy products. The company is in the clinical stage, meaning it is heavily investing in research and development to bring its therapies to market. This stage often involves high costs and limited revenue, impacting financial metrics like Return on Invested Capital (ROIC). REGENXBIO's ROIC is -62.38%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 11.40%. This negative ROIC ind...
PRNewsWire
Aug 8, 2024
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ROCKVILLE, Md. , Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C.
InvestorPlace
Aug 8, 2024
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Zacks Investment Research
Aug 6, 2024
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 234.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Parth Sanghvi
Aug 6, 2024
Regenxbio Reports Progress in Gene Therapy Programs: Key Takeaways from the Earnings Call
Regenxbio Reports Progress in Gene Therapy Programs: Key Takeaways from the Earnings Call Regenxbio has recently shared its Q2 earnings report, highlighting notable progress in its gene therapy programs. The company’s earnings call provided insights into its advancements and strategic focus, demonstrating its commitment to innovation in the biotechnology sector. Here’s a summary of Regenxbio’s recent performance and future outlook. Highlights from Regenxbio’s Earnings Call Progress in G...
Seeking Alpha
Aug 1, 2024
REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Patrick Christmas - CLO Curran Simpson - President and CEO Steve Pakola - CMO Vit Vasista - CFO Conference Call Participants Gena Wang - Barclays Vikram Purohit - Morgan Stanley Paul Choi - Goldman Sachs Annabel Samimy - Stifel C.J. Yeh - Leerink Partners Luca Issi - RBC Brian Skorney - Baird Daniil Gataulin - Chardan Capital Markets Operator Welcome everyone to the Q2 2024 REGENXBIO's E...
Zacks Investment Research
Aug 1, 2024
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $1.66 per share a year ago.
PRNewsWire
Jul 25, 2024
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m.
Zacks Investment Research
Jul 12, 2024
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research
Jun 25, 2024
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
